Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.-Reference-Cited by-同舟云学术

Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.

Published:2011-05-20 Issue:15_suppl Volume:29 Page:1028-1028
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Von Minckwitz G.,Kaufmann M.,Kuemmel S.,Fasching P. A.,Eiermann W.,Blohmer J. U.,Costa S. D.,Hilfrich J.,Jackisch C.,Gerber B.,Du Bois A.,Huober J. B.,Hanusch C. A.,Konecny G. E.,Fett W.,Stickeler E.,Harbeck N.,Mehta K.,Loibl S.,Untch M.,

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2011.29.15_suppl.1028

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment;Scientific Reports;2024-05-09

2. Comparison of the Efficacy and Safety of Docetaxel-Trastuzumab-Pertuzumab (DTP) with Standard 4-Doxorubicin and Cyclophosphamide (AC)-Taxan-Trastuzumab-Pertuzumab in Neoadjuvant Treatment of Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER-2) Positive Breast Cancer: a Turk Oncology Group (TOG) study.;2023-11-23

3. A Review of Endocrine Therapy in Early-stage Breast Cancer;American Journal of Clinical Oncology;2023-03-01

4. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study);Cancer Treatment and Research Communications;2023

5. Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy;Current Problems in Surgery;2022-09